Search - tctmd.com

Displaying 481 - 500 of 997

Sort: Relevancy | Date

News Daily News

Polypill Drops BP, LDL Cholesterol in a Disadvantaged US Population

Todd Neale

September 18, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Conference News ESC 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Michael O'Riordan

September 04, 2019

News Conference News ESC 2019

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Shelley Wood

September 03, 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Published Cohort

News Conference News ESC 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Yael L. Maxwell

September 03, 2019

News Conference News ESC 2019

Lifelong Exposure to Lower LDL and BP Linked With Big Reduction in CVD Events

Michael O'Riordan

September 02, 2019

News Conference News ESC 2019

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Michael O'Riordan

September 02, 2019

News Conference News ESC 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Yael L. Maxwell

August 31, 2019

News Daily News

Young Survivors of Childhood Cancer Have Higher, Earlier Risk of CVD Events

L.A. McKeown

August 30, 2019

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Todd Neale

August 23, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

Michael O'Riordan

August 21, 2019

News Daily News

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Yael L. Maxwell

August 14, 2019

News Daily News

Statin Discontinuation in the Elderly Linked to More CV Events

Yael L. Maxwell

August 01, 2019

News Daily News

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

Marcus A. Banks

July 25, 2019

News Daily News

Nonobstructive CAD on Cardiac CTA a Golden Opportunity to Boost Statin Prescribing

Michael O'Riordan

July 22, 2019

News Daily News

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Michael O'Riordan

July 19, 2019

News Daily News

CV Risk Factors in Youth May Prove Indelible for Later CAD

Marcus A. Banks

July 17, 2019

News Conference News SCCT 2019

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Yael L. Maxwell

July 15, 2019

Advertisement

Polypill Drops BP, LDL Cholesterol in a Disadvantaged US Population

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Lifelong Exposure to Lower LDL and BP Linked With Big Reduction in CVD Events

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Young Survivors of Childhood Cancer Have Higher, Earlier Risk of CVD Events

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Statin Discontinuation in the Elderly Linked to More CV Events

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

Nonobstructive CAD on Cardiac CTA a Golden Opportunity to Boost Statin Prescribing

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

CV Risk Factors in Youth May Prove Indelible for Later CAD

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content